Targeted drug delivery in cancer therapy

Technology in Cancer Research and Treatment

Volumn 4, Issue 4, 2005, Pages 363-374

  Vasir, Jaspreet K ^a   Labhasetwar, Vinod ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

And Anticancer agents; Bioconjugates; Nanoparticles; Tumor cells; Vasculature

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CHIMERIC PROTEIN; CREMOPHOR; DOXORUBICIN; DOXORUBICIN RGD 4C; FOLATE RECEPTOR; HORMONE RECEPTOR; IMMUNOTOXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOCAPSULE; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

CANCER CHEMOTHERAPY; CANCER THERAPY; CELL HETEROGENEITY; CONJUGATION; DRUG DELIVERY SYSTEM; ELECTRON SPIN RESONANCE; GENE TARGETING; HUMAN; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; PROSTATE CANCER; REVIEW;

EID: 24144445886     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460500400405     Document Type: Review

References (92)

1. Beardsley, T. A War not Won. Sci Am 270, 130-138 (1994).
2. Jain, R. K. Delivery of Molecular and Cellular Medicine to Solid Tumors. Adv Drug Deliv Rev 46, 149-168 (2001).
3. Jang, S. H., Wientjes, M. G., Lu, D., Au, J. L. Drug Delivery and Transport to Solid Tumors. Pharm Res 20, 1337-1350 (2003).
4. Chari, R. V. Targeted Delivery of Chemotherapeutics: Tumor-activated Prodrug Therapy. Adv Drug Deliv Rev 31, 89-104 (1998).
5. van Bree, C., Castro Kreder, N., Loves, W. J., Franken, N. A., Peters, G. J., Haveman, J. Sensitivity to Ionizing Radiation and Chemotherapeutic Agents in Gemcitabine-resistant Human Tumor Cell Lines. Int J Radiat Oncol Biol Phys 54, 237-244 (2002).
6. Krishna, R., Mayer, L. D. Multidrug Resistance (MDR) in Cancer. Mechanisms, Reversal Using Modulators of MDR and the Role of MDR Modulators in Influencing the Pharmacokinetics of Anticancer Drugs. Eur J Pharm Sci 11, 265-283 (2000).
7. Links, M., Brown, R. Clinical Relevance of the Molecular Mechanisms of Resistance to Anti-cancer Drugs. Expert Rev Mol Med 1999, 1-21 (1999).
8. Bennis, S., Chapey, C., Couvreur, P., Robert, J. Enhanced Cytotoxicity of Doxorubicin Encapsulated in Polyisohexylcyano-acrylate Nanospheres Against Multidrug-resistant Tumour Cells in Culture. Eur J Cancer 30A, 89-93 (1994).
9. Faneyte, I. F., Kristel, P. M., van de Vijver, M. J. Determining MDR1/P-glycoprotein Expression in Breast Cancer. Int J Cancer 93, 114-122 (2001).
10. Molinari, A., Calcabrini, A., Meschini, S., Stringaro, A., Crateri, P., Toccacieli, L., Marra, M., Colone, M., Cianfriglia, M., Arancia, G. Subcellular Detection and Localization of the Drug Transporter P-glycoprotein in Cultured Tumor Cells. Curr Protein Pept Sci 3, 653-670 (2002).
11. de Verdiere, A. C., Dubernet, C., Nemati, F., Soma, E., Appel, M., Ferte, J., Bernard, S., Puisieux, F., Couvreur, P. Reversion of Multidrug Resistance with Polyalkylcyanoacrylate Nanoparticles: Towards a Mechanism of Action. Br J Cancer 76, 198-205 (1997).
12. Maeda, H., Seymour, L. W., Miyamoto, Y. Conjugates of Anticancer Agents and Polymers: Advantages of Macromolecular Therapeutics In Vivo. Bioconjug Chem 3, 351-362 (1992).
13. Lasic, D. D. Doxorubicin in Sterically Stabilized Liposomes. Nature 380, 561-562 (1996).
14. Kakizawa, Y., Kataoka, K. Block Copolymer Micelles for Delivery of Gene and Related Compounds. Adv Drug Deliv Rev 54, 203-222 (2002).
15. Kataoka, K., Harada, A., Nagasaki, Y. Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance. Adv Drug Deliv Rev 47, 113-131 (2001).
16. Calcabrini, A., Meschini, S., Stringaro, A., Cianfriglia, M., Arancia, G., Molinari, A. Detection of P-glycoprotein in the Nuclear Envelope of Multidrug Resistant Cells. Histochem J 32, 599-606 (2000).
17. Fu, L. W., Zhang, Y. M., Liang, Y. J., Yang, X. P., Pan, Q. C. The Multidrug Resistance of Tumour Cells was Reversed by Tetrandrine In Vitro and in Xenografts Derived from Human Breast Adenocarcinoma MCF-7/adr Cells. Eur J Cancer 38, 418-426 (2002).
18. Arancia, G., Molinari, A., Calcabrini, A., Meschini, S., Cianfriglia, M. Intracellular P-glycoprotein in Multidrug Resistant Tumor Cells. Ital J Anat Embryol 106, 59-68 (2001).
19. Minko, T., Paranjpe, P. V., Qiu, B., Lalloo, A., Won, R., Stein, S., Sinko, P. J. Enhancing the Anticancer Efficacy of Camptothecin Using Biotinylated Poly(ethylene glycol) Conjugates in Sensitive and Multidrug-resistant Human Ovarian Carcinoma Cells. Cancer Chemother Pharmacol 50, 143-150 (2002).
20. Sahoo, S. K., Labhasetwar, V. Enhanced Antiproliferative Activity of Transferrin-conjugated Paclitaxel-loaded Nanoparticles is Mediated via Sustained Intracellular Drug Retention. Mol Pharm. in press (2005).
21. Au, J. L., Jang, S. H., Zheng, J., Chen, C. T., Song, S., Hu, L., Wientjes, M. G. Determinants of Drug Delivery and Transport to Solid Tumors. J Control Release 74, 31-46 (2001).
22. Au, J. L., Jang, S. H., Wientjes, M. G. Clinical Aspects of Drug Delivery to Tumors. J Control Release 78, 81-95 (2002).
23. Rubin, P., Casarett, G. Microcirculation of Tumors. I. Anatomy, Function, and Necrosis. Clin Radiol 17, 220-229 (1966).
24. Shubik, P. Vascularization of Tumors: A Review. J Cancer Res Clin Oncol 103, 211-226 (1982).
25. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., Jain, R. K. Regulation of Transport Pathways in Tumor Vessels: Role of Tumor Type and Microenvironment. Proc Natl Acad Sci USA 95, 4607-4612 (1998).
26. Yuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., Jain, R. K. Vascular Permeability and Microcirculation of Gliomas and Mammary Carcinomas Transplanted in Rat and Mouse Cranial Windows. Cancer Res 54, 4564-4568 (1994).
27. Dellian, M., Witwer, B. P., Salehi, H. A., Yuan, F., Jain, R. K. Quantitation and Physiological Characterization of Angiogenic Vessels in Mice: Effect of Basic Fibroblast Growth Factor, Vascular Endothelial Growth Factor/Vascular Permeability Factor, and Host Microenvironment. Am J Pathol 149, 59-71 (1996).
28. Maeda, H., Wu, J., Sawa, T., Matsumura, Y, Hori, K. Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review. J Control Release 65, 271-284 (2000).
29. Matsumura, Y., Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res 46, 6387-6392 (1986).
30. Muggia, F. M. Doxorubicin-polymer Conjugates: Further Demonstration of the Concept of Enhanced Permeability and Retention. Clin Cancer Res 5, 7-8 (1999).
31. Moghimi, S. M., Hunter, A. C., Murray, J. C. Long-circulating and Target-specific Nanoparticles: Theory to Practice. Pharmacol Rev 53, 283-318 (2001).
32. Duncan, R., Sat, Y. N. Tumor Targeting by Enhanced Permeability and Retention (EPR) Effect. Ann. Oncol. 9, 39 (1998).
33. Gregoriadis, G. Engineering Liposomes for Drug Delivery: Progress and Problems. Trends Biotechnol 13, 527-537 (1995).
34. Fujita, T., Nishikawa, M., Tamaki, C., Takakura, Y., Hashida, M., Sezaki, H. Targeted Delivery of Human Recombinant Superoxide Dismutase by Chemical Modification with Mono- and Polysaccharide Derivatives. J Pharmacol Exp Ther 263, 971-978 (1992).
35. Seymour, L. W., Duncan, R., Kopeckova, P., Kopecek, J. Daunomycin- and Adriamycin-N-(2-hydroxypropyl)methacrylamide Copolymer Conjugates; Toxicity Reduction by Improved Drug-delivery. Cancer Treat Rev 14, 319-327 (1987).
36. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I., Cable, H. C., Pohl, J., Lloyd, J. B., Kopecek, J. Anticancer Agents Coupled to N-(2-hydroxypropyl)methacrylamide Copolymers. I. Evaluation of Daunomycin and Puromycin Conjugates In Vitro. Br J Cancer 55, 165-174 (1987).
37. Maeda, H., Ueda, M., Morinaga, T., Matsumoto, T. Conjugation of Poly(styrene-co-maleic Acid) Derivatives to the Antitumor Protein Neocarzinostatin: Pronounced Improvements in Pharmacological Properties. J Med Chem 28, 455-461 (1985).
38. Kimoto, A., Konno, T., Kawaguchi, T., Miyauchi, Y., Maeda, H. Antitumor Effects of SMANCS on Rat Mammary Tumor Induced by 7,12-dimethylbenz[a] anthracene. Cancer Res 52, 1013-1017 (1992).
39. Konno, T. Targeting Chemotherapy for Hepatoma: Arterial Administration of Anticancer Drugs Dissolved in Lipiodol. Eur J Cancer 28, 403-409 (1992).
40. Zlotecki, R. A., Boucher, Y., Lee, I., Baxter, L. T., Jain, R. K. Effect of Angiotensin II Induced Hypertension on Tumor Blood Flow and Interstitial Fluid Pressure. Cancer Res 53, 2466-2468 (1993).
41. Garzotto, M., Hudson, R. G., Peters, L., Hsieh, Y. C., Barrera, E., Mori, M., Beer, T. M., Klein, T. Predictive Modeling for the Presence of Prostate Carcinoma Using Clinical, Laboratory, and Ultrasound Parameters in Patients with Prostate Specific Antigen Levels < or = 10 ng/mL. Cancer 98, 1417-1422 (2003).
42. Caplan, A., Kratz, A. Prostate-specific Antigen and the Early Diagnosis of Prostate Cancer. Am J Clin Pathol 117 Suppl, S104-108 (2002).
43. Gleave, M. E., Coupland, D., Drachenberg, D., Cohen, L., Kwong, S., Goldenberg, S. L., Sullivan, L. D. Ability of Serum Prostate-specific Antigen Levels to Predict Normal Bone Scans in Patients with Newly Diagnosed Prostate Cancer. Urology 47, 708-712 (1996).
44. Sahoo, S. K., Ma, W., Labhasetwar, V. Efficacy of Transferrin-conjugated Paclitaxel-loaded Nanoparticles in a Murine Model of Prostate Cancer. Int J Cancer 112, 335-340 (2004).
45. Rapoport, N. Combined Cancer Therapy by Micellar-encapsulated Drug and Ultrasound. Int J Pharm 277, 155-162 (2004).
46. Rapoport, N., Marin, A., Luo, Y., Prestwich, G. D., Muniruzzaman, M. D. Intracellular Uptake and Trafficking of Pluronic Micelles in Drug-sensitive and MDR Cells: Effect on the Intracellular Drug Localization. J Pharm Sci 91, 157-170 (2002).
47. Husseini, G. A., Christensen, D. A., Rapoport, N. Y., Pitt, W. G. Ultrasonic Release of Doxorubicin From Pluronic P105 Micelles Stabilized with an Interpenetrating Network of N,N-diethylacrylamide. J Control Release 83, 303-305 (2002).
48. Rapoport, N. Y., Christensen, D. A., Fain, H. D., Barrows, L., Gao, Z. Ultrasound-triggered Drug Targeting of Tumors In Vitro and In Vivo. Ultrasonics 42, 943-950 (2004).
49. Marin, A., Sun, H., Husseini, G. A., Pitt, W. G., Christensen, D. A., Rapoport, N. Y. Drug Delivery in Pluronic Micelles: Effect of High-frequency Ultrasound on Drug Release from Micelles and Intracellular Uptake. J Control Release 84, 39-47 (2002).
50. Hafeli, U. O. Magnetically Modulated Therapeutic Systems. Int J Pharm 277, 19-24 (2004).
51. Lubbe, A. S., Bergemann, C., Riess, H., Schriever, F., Reichardt, P., Possinger, K., Matthias, M., Dorken, B., Herrmann, F., Gurtler, R., Hohenberger, P., Haas, N., Sohr, R., Sander, B., Lemke, A. J., Ohlendorf, D., Huhnt, W., Huhn, D. Clinical Experiences with Magnetic Drug Targeting: A Phase I Study with 4′-epidoxorubicin in 14 Patients with Advanced Solid Tumors. Cancer Res 56, 4686-4693 (1996).
52. Lubbe, A. S., Alexiou, C., Bergemann, C. Clinical Applications of Magnetic Drug Targeting. J Surg Res 95, 200-206 (2001).
53. Alexiou, C., Arnold, W., Klein, R. J., Parak, F. G., Hulin, P., Bergemann, C., Erhardt, W., Wagenpfeil, S., Lubbe, A. S. Locoregional Cancer Treatment with Magnetic Drug Targeting. Cancer Res 60, 6641-6648 (2000).
54. Jain, T. K., Morales, M. A., Sahoo, S. K., Leslie-Pelecky, D., Labhasetwar, V. Iron-oxide Nanoparticles for Sustained Delivery of Anticancer Agents. Mol Pharm 2, 194-205 (2005).
55. Hafeli, U. Radioactive Magnetic Microspheres, in Microspheres, Microcapsules & Liposomes: Magneto- and Radio-pharmaceuticals, pp. 559-584. Ed., Arshady, R. Citus Books, London (2001).
56. Molema, G., Meijer, D. K., de Leij, L. F. Tumor Vasculature Targeted Therapies: Getting the Players Organized. Biochem Pharmacol 55, 1939-1945 (1998).
57. Schnitzer, J. E. Vascular Targeting as a Strategy for Cancer Therapy. N Engl J Med 339, 472-474 (1998).
58. Folkman, J., Watson, K., Ingber, D., Hanahan, D. Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia. Nature 339, 58-61 (1989).
59. Molema, G., de Leij, L. F., Meijer, D. K. Tumor Vascular Endothelium: Barrier or Target in Tumor Directed Drug Delivery and Immunotherapy. Pharm Res 14, 2-10 (1997).
60. Thorpe, P. E. Vascular Targeting Agents as Cancer Therapeutics. Clin Cancer Res 10, 415-427 (2004).
61. Fonsatti, E., Altomonte, M., Arslan, P., Maio, M. Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy. Curr Drug Targets 4, 291-296 (2003).
62. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., Ferrara, N. Inhibition of Vascular Endothelial Growth Factor-induced Angiogenesis Suppresses Tumour Growth In Vivo. Nature 362, 841-844 (1993).
63. Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., Bergsland, E. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/leucovorin (LV) with FU/LV Alone in Patients with Metastatic Colorectal Cancer. J Clin Oncol 21, 60-65 (2003).
64. Liao, F., Doody, J. F., Overholser, J., Finnerty, B., Bassi, R., Wu, Y., Dejana, E., Kussie, P., Bohlen, P., Hicklin, D. J. Selective Targeting of Angiogenic Tumor Vasculature by Vascular Endothelial-cadherin Antibody Inhibits Tumor Growth Without Affecting Vascular Permeability. Cancer Res 62, 2567-2575 (2002).
65. Arap, W., Pasqualini, R., Ruoslahti, E. Chemotherapy Targeted to Tumor Vasculature. Curr Opin Oncol 10, 560-565 (1998).
66. Arap, W., Pasqualini, R., Ruoslahti, E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science 279, 377-380 (1998).
67. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., Cheresh, D. A. Integrin Alpha v Beta 3 Antagonists Promote Tumor Tegression by Inducing Apoptosis of Angiogenic Blood Vessels. Cell 79, 1157-1164 (1994).
68. Brooks, P. C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F. H., Cheresh, D. A. Antiintegrin Alpha v Beta 3 Blocks Human Breast Cancer Growth and Angiogenesis in Human Skin. J Clin Invest 96, 1815-1822 (1995).
69. Houshmand, P., Zlotnik, A. Targeting Tumor Cells. Curr Opin Cell Biol 15, 640-644 (2003).
70. Stevanovic, S. Identification of Tumour-associated T-cell Epitopes for Vaccine Development. Nat Rev Cancer 2, 514-520 (2002).
71. Juretic, A., Spagnoli, G. C., Schultz-Thater, E., Sarcevic, B. Cancer/ Testis Tumour-associated Antigens: Immunohistochemical Detection with Monoclonal Antibodies. Lancet Oncol 4, 104-109 (2003).
72. Kobayashi, T., Yamaguchi, M., Kim, S., Morikawa, J., Ogawa, S., Ueno, S., Sun, E., Dougherty, E., Shmulevich, I., Shiku, H., Zhang, W. Microarray Reveals Differences in Both Tumors and Vascular Specific Gene Expression in De Novo CD5+ and CD5- Diffuse Large B-cell Lymphomas. Cancer Res 63, 60-66 (2003).
73. Sudimack, J., Lee, R. J. Targeted Drug Delivery via the Folate Receptor. Adv Drug Deliv Rev 41, 147-162 (2000).
74. Chung, N. S., Wasan, K. M. Potential Role of the Low-density Lipoprotein Receptor Family as Mediators of Cellular Drug Uptake. Adv Drug Deliv Rev 56, 1315-1334 (2004).
75. Amin, K., Ng, K. Y., Brown, C. S., Bruno, M. S., Heath, T. D. LDL Induced Association of Anionic Liposomes with Cells and Delivery of Contents as Shown by the Increase in Potency of Liposome Dependent Drugs. Pharm Res 18, 914-921 (2001).
76. Schally, A. V., Nagy, A. Chemotherapy Targeted to Cancers Through Tumoral Hormone Receptors. Trends Endocrinol Metab 15, 300-310 (2004).
77. Ben-Yehudah, A., Lorberboum-Galski, H. Targeted Cancer Therapy with Gonadotropin-releasing Hormone Chimeric Proteins. Expert Rev Anticancer Ther 4, 151-161 (2004).
78. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marion, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., Friend, S. H. Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer. Nature 415, 530-536 (2002).
79. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Bernards, R., Friend, S. H. Expression Profiling Predicts Outcome in Breast Cancer. Breast Cancer Res 5, 57-58 (2003).
80. Vasir, J. K., Reddy, M. K., Labhasetwar, V. Nanosystems in Drug Targeting: Opportunities and Challenges. Curr Nanoscience 1, 47-64 (2005).
81. Hudson, P. J., Souriau, C. Engineered Antibodies. Nat Med 9, 129-134 (2003).
82. Jain, R. K., Baxter, L. T. Mechanisms of Heterogeneous Distribution of Monoclonal Antibodies and Other Macromolecules in Tumors: Significance of Elevated Interstitial Pressure. Cancer Res 48, 7022-7032 (1988).
83. Aina, O. H., Sroka, T. C., Chen, M. L., Lam, K. S. Therapeutic Cancer Targeting Peptides. Biopolymers 66, 184-199 (2002).
84. Niv, R., Cohen, C. J., Denkberg, G., Segal, D., Reiter, Y. Antibody Engineering for Targeted Therapy of Cancer: Recombinant Fv-immunotoxins. Curr Pharm Biotechnol 2, 19-46 (2001).
85. Reiter, Y. Recombinant Immunotoxins in Targeted Cancer Cell Therapy. Adv Cancer Res 81, 93-124 (2001).
86. Nechushtan, A., Yarkoni, S., Marianovsky, I., Lorberboum-Galski, H. Adenocarcinoma Cells are Targeted by the New GnRH-PE66 Chimeric Toxin Through Specific Gonadotropin-releasing Hormone Binding Sites. J Biol Chem 272, 11597-11603 (1997).
87. Aqeilan, R., Yarkoni, S., Lorberboum-Galski, H. Interleukin 2-Bax: A Novel Prototype of Human Chimeric Proteins for Targeted Therapy. FEBS Lett 457, 271-276 (1999).
88. Nobs, L., Buchegger, F., Gumy, R., Allemann, E. Current Methods for Attaching Targeting Ligands to Liposomes and Nanoparticles. J Pharm Sci 93, 1980-1992 (2004).
89. Shi, G., Guo, W., Stephenson, S. M., Lee, R. J. Efficient Intracellular Drug and Gene Delivery Using Folate Receptor-targeted pH-sensitive Liposomes Composed of Cationic/Anionic Lipid Combinations. J Control Release 80, 309-319 (2002).
90. Coleman, R. E. Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies. Cancer Treat Rev 27, 165-176 (2001).
91. Mundy, G. R. Metastasis to Bone: Causes, Consequences and Therapeutic Opportunities. Nat Rev Cancer 2, 584-593 (2002).
92. Bagi, C. M. Targeting of Therapeutic Agents to Bone to Treat Metastatic Cancer. Adv Drug Deliv Rev 57, 995-1010 (2005).